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Abstract
Background: Systems-level approaches are increasingly common in both murine and human translational studies.
These approaches employ multiple high information content assays. As a result, there is a need for tools to
integrate heterogeneous types of laboratory and clinical/demographic data, and to allow the exploration of that
data by aggregating and/or segregating results based on particular variables (e.g., mean cytokine levels by age and
gender).
Methods: Here we describe the application of standard data warehousing tools to create a novel environment for
user-driven upload, integration, and exploration of heterogeneous data. The system presented here currently
supports flow cytometry and immunoassays performed in the Stanford Human Immune Monitoring Center, but
could be applied more generally.
Results: Users upload assay results contained in platform-specific spreadsheets of a defined format, and clinical
and demographic data in spreadsheets of flexible format. Users then map sample IDs to connect the assay results
with the metadata. An OLAP (on-line analytical processing) data exploration interface allows filtering and display of
various dimensions (e.g., Luminex analytes in rows, treatment group in columns, filtered on a particular study).
Statistics such as mean, median, and N can be displayed. The views can be expanded or contracted to aggregate
or segregate data at various levels. Individual-level data is accessible with a single click. The result is a user-driven
system that permits data integration and exploration in a variety of settings. We show how the system can be
used to find gender-specific differences in serum cytokine levels, and compare them across experiments and assay
types.
Conclusions: We have used the tools and techniques of data warehousing, including open-source business
intelligence software, to support investigator-driven data integration and mining of diverse immunological data.
Keywords: Systems immunology, Data integration, Data warehousing, OLAP
Background
Increasingly, translational studies in medicine take a “sys-
tems biology” approach, meaning that comprehensive
measurements of many parameters are made, not just
those hypothesized to be directly involved in the condition
being studied. To accomplish this, multiple analytical plat-
forms are often employed, such as gene expression, flow
cytometry, and immunoassays. The data from all these
platforms must then be integrated, along with metadata
(such as clinical and demographic information), to under-
stand the results as a whole.
As an example of a systems-level immunology study,
we are currently investigating the effects of aging on
immune responsiveness, as measured by influenza vacci-
nation. In this study, healthy participants across a range
of ages have blood samples taken at three time points
before and after being administered an influenza vaccine.
Responsiveness is measured by hemagglutinin inhibition
(HAI). The particpants’ immune systems are character-
ized at the cellular level by flow cytometry, at the geno-
mic level by gene expression microarray, and at the
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kines. Relevant clinical parameters include age, gender,
ethnicity, and the type of vaccine administered. All these
variables need to be analyzed in a combined fashion.
Similar studies are underway at other centers [1], and
these data could potentially be integrated for additional
mining.
Tools to easily integrate disparate data types and mine
their combined results are currently not well developed
for biology or medicine. We therefore set out to create a
system for data integration and mining that would allow
for the comparison of data across assay platforms and
even across studies. Our requirements for the system
included: (1) a reasonable development time and cost; (2)
user-driven data management, with minimal programmer
intervention; (3) support for user-driven data exploration
with a shallow learning curve; and (4) support for multiple
investigators and projects. We refer to the resulting system
as the SDM for “Stanford Data Miner”.
To accomplish these goals, we leveraged established
techniques of data warehousing, a discipline designed to
integrate heterogeneous data in a consistent fashion in
support of analysis and decision making [2,3]. A data
warehouse has three main components: the dimensional
model, back-end processes for data integration, and end-
user tools for exploration and analysis. We discuss each
of these components in the following sections. In addi-
tion, we used open source software for the database, the
web application server, and interactive data analysis.
Furthermore, we deployed the system on cloud servers
for ease of access, speed of procurement, and low
ongoing costs.
Methods and materials
The work is implemented as two web applications (“web
apps”) running under JBoss AS, an open source Java-EE-
based application server, on a Rackspace Cloud Server
running Ubuntu Linux. One web app is for data integra-
tion; the other is for data exploration. Source code is avail-
able at http://stanfordminer.sourceforge.net.
Data integration web app
This is a fully custom Java “Web 2.0” product called
Sherpa. Sherpa consists of around 11,000 lines of Java,
2,000 lines of XHTML (facelets), and 2,000 lines of other
text (mostly properties and configuration files). Though
fully custom, it is built using several open-source frame-
works and toolkits. Chief among these is Seam, a plat-
form integrating Asynchronous JavaScript and XML
(AJAX), JavaServer Faces (JSF), the Java Persistence API
(JPA), and Enterprise Java Beans (EJB) 3.0. From the
JBoss RichFaces project (an advanced user interface com-
ponent framework), Sherpa draws user interface compo-
nents such as the calendar, the tab panel, the modal
panel, and the extended data table, as well as AJAX sup-
port through the project’s a4j library. Sherpa’sd r a g - a n d -
drop capability is provided by the open source JavaScript
toolkit Dojo, extended for Sherpa’s specific needs. Sherpa
accesses Excel spreadsheets by means of Apache POI, a
Java API for Microsoft documents.
Data exploration web app
This is an open source business intelligence product called
JasperServer (version 3.7), customized through supported
configuration changes. JasperServer incorporates the Mon-
drian OLAP implementation, with a JPivot user interface.
The OLAP interface in JasperServer provides functionality
through a logical layer on top of an underlying relational
database, in contrast to OLAP implementations requiring
a special purpose data storage format. Thus it is known as
relational OLAP, or ROLAP. Mondrian schemas, defined
in XML, map the underlying database structure into an
OLAP structure. Both web apps use the open source data-
base engine MySQL for back-end data persistence.
Users authenticate to the two web apps individually, by
user name and password. All web access to the Cloud
Server uses HTTPS. Command-line access is through
SSH, with only passwordless (public key) authentication
allowed.
Luminex assays
Data shown in the Results is based on a study of serum
from 434 healthy participants, each sampled three times
(before and 7 and 28 days post-flu vaccination). Lumi-
nex assays were performed using a custom 51-plex kit
from Affymetrix (Santa Clara, CA). A list of analytes
and protocol is available at http://iti.stanford.edu/
research/himc-protocols-immunoassays.html. Some sam-
ples were tested twice using a second batch (different
lot) of Luminex kits. Values from all three visits were
included in the data shown.
MesoScale Discovery (MSD) assays
These were performed according to the manufacturer’s
instructions http://www.mesoscale.com. A 4-plex cyto-
kine assay (IL-1b, IL-6, IL-8, TNF) was performed on the
same healthy participants at the same timepoints as
described for Luminex assays above.
Phosphoepitope flow cytometry assays
These were performed as described http://iti.stanford.edu/
research/himc-protocols-flowcytometry.html. Briefly, cryo-
preserved PBMC were thawed, rested 1 h at 37°C, and sti-
mulated for 15 min using saturating amounts of individual
cytokines (IFNa,I F N g, IL-2, IL-6, IL-7, IL-10, or IL-21) or
left unstimulated. They were then fixed, permeabilized,
and stained for surface markers and phospho-STAT1,
phospho-STAT3, and phospho-STAT5.
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approved by Stanford’s Institutional Review Board, with
written informed consent obtained from all participants.
Results
Data model
One important goal of this work was to facilitate data
analysis. Thus we employed dimensional modeling, a
well-established technique from data warehousing.
Dimensional modeling has been in use since the late
1960s [2]. The technique organizes data in a way that is
easy to understand and provides high-performance
access. In a dimensional model, a numeric fact about the
domain is described by many attributes, called dimen-
sions. As illustrated in Figure 1, our dimensional model
is centered on the aliquot_fact table, which is further
described by parameters describing the person, sample,
analyte, and source document. Dimensional models are
sometimes called star schemas because the illustration of
the model resembles a star.
The aliquot_fact table, in conjunction with the ana-
lyte table, is designed to hold numeric results from
multiple assays. The three main fields that support this
are analyte, readout, and units. This generic structure
supports results from diverse assays such as Luminex,
flow phenotyping, and phospho-flow; and is easily
extensible to more assays. Luminex data includes ana-
lytes such as CD40Ligand, IL-6, and VEGF; and units
such as raw MFI, average MFI, and pg/ml. Flow pheno-
typing data includes analytes such as Lymph/CD3
+/CD4+ and Lymph/CD3+/CD8+/CD28+ and units
such as percent of parent population. This table also
has a field for quantification (in range, below LOQ
(limit of quantification), above LOQ), which we use to
classify results from the Luminex and MSD calibration
algorithms.
Figure 1 Dimensional data model. An aliquot_fact, or single experimental data point, is associated in our dimensional model with the
additional dimensions of person, sample, analyte, and data source. This schema provides a simple way to represent and associate
heterogeneous translational data.
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are included in the aliquot_fact table. Tissue includes such
values as cryopreserved PBMC, cryopreserved serum, and
fresh plasma. Tissue is recorded at an aliquot level since a
single sample (e.g. whole blood) can be processed into ali-
quots of different tissues such as PBMC and serum. Stim
includes values such as IFNg, IL-2, and IL-10, thereby cap-
turing different stimulation conditions used in functional
assays. The aliquot_fact table joins to the analyte, person,
sample, and source tables with foreign keys.
The sample table includes the time point hierarchy, con-
sisting of the fields year, month, week, day, and draw.
These fields do not record calendar dates. Instead, they
record the sequence and structure of study events. For
example, in some studies, samples might be drawn on day
0, day 1, day 7, and day 28. These values are recorded in
the day field. In a study that followed the same patient
from year to year, the value for year would be recorded in
the year field. In another study, samples might be drawn
at week 0, week 5, and week 12. These values are recorded
in the week field. In a third study, samples might be drawn
on 3 subsequent days (day 1, day 2, and day 3), 3 different
times a day (e.g., 10:00 AM, 12:00 PM, and 2:00 PM).
Thus, our time point hierarchy supports many different
study designs while capturing the natural structure of
time.
The person table is designed to capture time-invariant
characteristics of study participants that might be relevant
to interpretation of study results. These include gender,
ethnicity, and condition. While condition is often equiva-
lent to disease, the field is designed to also support more
general classifications (e.g. pregnant, antibody-positive).
The person table also includes attributes for treatment
and response. Treatment values could be as general as
treated and placebo, or more study-specific such as cohort
A, cohort B, and cohort C. Similarly, response could be as
generic as responder and non-responder, or more specific
such as partial response, complete response, stable, or pro-
gressive disease.
The source table records information about the batch
results spreadsheets that contained the original data
loaded into the database. Important attributes include file
name, upload date, assay (e.g. Human Luminex 51plex,
Flow phenotyping, Cytokine-stimulated phospho-flow),
and assay run date. These fields support minimal infor-
m a t i o ns t a n d a r d ss u c ha sM I A T A[ 4 ]a n dM I F l o w C y t
[5]. Additionally, the source table includes PI (principal
investigator) and project, allowing us to group data based
on a specific project or study, and on PI.
User-driven data integration
The second component of a data warehouse is the set of
backend processes for transforming and loading data
into the dimensional model. Two related goals of this
work were to accomplish data integration within a rea-
sonable time and cost, and to support user-driven inte-
gration with minimal programmer intervention. This
section describes the web-based user interfaces that
allow users to upload batch results from sets of aliquots
analyzed with a particular assay, and to upload metadata
describing persons and samples. In both cases, the data
is uploaded from Excel spreadsheets to the data tables
previously described. There are constraints around the
format of the spreadsheets for batch results for particu-
lar assays, which were designed around the existing for-
mat of reports being generated in our laboratory.
Generally, samples are reported in rows, with analytes in
columns. Metadata spreadsheets can be more flexible in
format, allowing virtually any kind of clinical and demo-
graphic data to be displayed in columns, with persons
or samples in rows.
The system makes no assumptions about the order in
which batch results or experiment metadata are loaded.
Once batch results and experiment metadata have been
loaded into the database, connections between aliquot
identifiers and sample identifiers and between sample
identifiers and person identifiers can be established.
Screen capture videos of representative workflows are
included in the Additional file 1: Video S1, Additional
file 2: Video S2, Additional file 3: Video S3.
The Upload Batch Results page allows the user to select
a spreadsheet containing assay results and classify the file
according to attributes such as operator, run date, assay,
instrument, tissue, and time point. Upon upload, the
spreadsheet is parsed and loaded into the database. Cus-
tom Java code parses the spreadsheets, handling lab-spe-
cific data organization for each assay. The original file is
also posted on a web-based project management system
(Basecamp, http://www.basecamphq.com) for future
reference.
The Upload Experiment Metadata page, illustrated in
Figure 2, allows the user to add clinical and/or demo-
graphic data from a spreadsheet. The only format con-
straint is that records be in rows with attributes in
columns. The user maps spreadsheet columns to under-
lying database columns. Attributes associated with per-
son (e.g. Condition, Ethnicity, and Gender) are displayed
in the left hand column. Those associated with sample
are displayed in the right hand column. Once the user
specifies the spreadsheet column that contains either Per-
son ID or Sample ID, the relevant attributes are activated
for selection and mapping. Attributes with associated
Map Values buttons are validated against a list of valid
values. After selecting Map Values for a particular attri-
bute, the user is presented with the Map Values page, as
shown in Figure 3. This page supports drag and drop
mapping of incoming values to a controlled vocabulary of
valid values. Some valid values are specified at a global
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are project-specific (e.g. Response, Treatment, and Time-
point). Once the user has mapped values for all relevant
attributes the data may be uploaded.
The Map Batch Results to Metadata (Figure 4) and the
Map Sample to Person pages (not shown) support these
identifier mapping tasks. The interface allows the user to
drag values from the right hand column (e.g. Sample IDs)
to the left hand column (e.g. Aliquot IDs). Values on the
left hand side can be filtered by incoming document, lim-
iting the mapping task to a certain report (e.g. the one
just uploaded) or set of reports (e.g. Luminex reports).
Figure 2 Upload Experiment Metadata page. A spreadsheet containing clinical and/or demographic “metadata” is uploaded and its contents
displayed at the top of the page. In the lower half of the page, one can select which columns of the spreadsheet represent specific “Person” or
“Sample” attributes. In this example, Person ID has been specified and the associated attributes are active. Sample ID has not been specified, so
those attributes are inactive. Once an attribute has been mapped to a column, the associated Map Values button is activated (see Gender).
Figure 3 Map Valid Values page. The terms in certain columns (e.g. Condition, Ethnicity, and Gender) are mapped against a set of defined
“valid values” for that attribute. In this way, a controlled vocabulary may be maintained even when terminology on incoming spreadsheets
varies (e.g., “M” and “F” versus “male” and “female”, “SLE” versus “lupus”, etc.).
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list facilitates the derivation of equal values from both
lists, allowing the users to take advantage of the Map
Equals button. When the user confirms the mappings,
the database IDs in the child table are updated with the
database IDs for the mapped values in the parent table
(e.g. aliquot_fact is updated with sample_id).
Investigator-driven data exploration
The third component of a data warehouse is a set of end-
user tools for data exploration and analysis. To support
investigator-driven exploration, we deployed JasperServer,
an open source business intelligence suite. We used this
suite to provide an on-line analytical processing (OLAP)
interface for our integrated data. OLAP provides a means
of organizing data and an associated user interface that is
designed to support interactive exploratory data analysis.
Starting with a relatively simple table summarizing the
data, the user can drill down into the data. The user can
also drill through into the underlying detail. OLAP has
been used in the biological sciences to support analysis of
time series gene expression data [6], protein folding simu-
lation results [7], and climate-related health vulnerabilities
[8].
The OLAP logical model organizes data in a multidimen-
sional “cube,” with facts (also known as measures)
described by dimensions. Thus, our OLAP model is an
extension of our dimensional data model as described
above. One starting view of the data is shown in Figure 5A.
This has been filtered on 2009 and 2010 data from our
influenza vaccine study described in the Introduction.
From this view, it can be readily seen which assays were
done at which timepoints, and how many data points are
available. The investigator can expand analytes associated
with any or all assays on the rows. Notice that the time
point dimension, which has been placed as a column, has
already been expanded so that data for Day00, Day07, and
Day28 are visible. A drill-down into specific Luminex ana-
lytes is shown in Figure 5B. Kit batch numbers have been
added to the rows to further segregate the data by lot, and
gender has been placed in the columns. “Mean” has been
added as a Measure, in addition to “N” (number of data
points). Graphs of the displayed data can be viewed and
exported, as also shown at the bottom of Figure 5B. At
these aggregate levels, the readout value is an average of all
underlying data points. By clicking on the number in any
particular cell, the investigator can see underlying data, as
shown in Additional file 4: Table S1.
The results shown in Figure 5B serve to show how
quickly a research question can be explored in SDM. In
this case, we decided to explore possible gender differ-
ences in serum cytokine levels, using data from a large
cohort of healthy participants. In a brief scan of aggre-
gated mean immunoassay results by gender, 4 of 51 cyto-
kines appeared to show a gender bias of > 20% (ENA-78,
GM-CSF, leptin, and PDGFbb). Further segregating by
lot number shows that the differences are reproducible
across two lots of Luminex kits, and are also apparent,
Figure 4 Map Batch Results to Sample page. Once sample metadata is uploaded, it needs to be “mapped” to laboratory data (batch results).
This page allows the user to select a set of batch results (lower left), then map the aliquot IDs in those batch results to sample IDs from the
uploaded metadata. Often, these don’t fully match due to prefixes and suffixes that were added by the laboratory analysis software, so controls
at the top of this page help to quickly remove such “artifacts”. Once the IDs are made to match, the “Map Equals” button allows all matching
IDs to be mapped at once. Alternately, individual IDs can be dragged and dropped from the Sample ID column to the Batch Results column to
map them.
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Discovery). While not shown in the Figure, statistics like
minimum, maximum, and median values can also be
displayed to better judge the results. (We plan to add
additional statistics, like SD and %CV in a future release.)
Or, the calculated concentrations rather than raw values
Cytokine:     ___ENA78___  ______GM-CSF______  ___PDGFEE___                ___Leptin___ 
Batch:          H51-1    H51-2   H51-1   H51-2    H 9-2    H51-1    H51-2                 H51-1   H51-2 
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Figure 5 (A) Assay group by Sample Day. This OLAP cube displays aggregated data from each of three different assay types, and groups
them by time point (day 0, 7, and 28). It is immediately apparent which assays were performed at which time points. (B) Identification of
cytokines with gender bias. Expanding the Analytes dimension, and diplaying Gender in columns, we have selected those cytokines (4 of 51
analyzed) that show > 20% difference in mean expression between males and females. By also displaying Lot # in rows, we can see that the
trends are preserved across two different lots of Luminex kits (H51-1 and H51-2), although absolute values vary by lot. For GM-CSF, the trend is
also seen in a different type of assay (MSD 9-plex, shown as lot H9-2, 4/10). Other cytokines were not run in this assay type, so the cross-
platform comparison can only be made for GM-CSF. Gender biases of the type shown here have been previously reported for ENA-78 [9], leptin
[10,11], and PDGF [12], but to our knowledge not for GM-CSF. “Mean” indicates the mean MFI (median fluorescence intensity) of the indicated
number of samples (N). Graphs of the data are exported from the native application to demonstrate the graphing functions of SDM.
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can be segregated by age band to test whether there is an
age bias as well. Given that there were no significant dif-
ferences in these cytokines by age band, the gender
effects shown do not appear to be confounded by an age
effect, though we have not formally ruled this out. Inter-
estingly, gender differences have been previously
described for ENA-78 (CXCL5) [9], leptin [10,11], and
PDGF [12], but not to our knowledge for GM-CSF. We
are investigating whether the GM-CSF difference is
reproduced in other studies, and what the basis of this
difference might be.
We have also used SDM to find relationships in data
across assay platforms in our influenza study. For exam-
ple, while we did not find a significant gender difference
for serum IL-6 by Luminex, we did find such a difference
using a more sensitive chemiluminescence assay (MSD).
Furthermore, this difference, in which females had a
higher mean IL-6 level than males, corresponded to a
reduced mean induction of pSTAT1 in response to IL-6 in
CD4+ T cells, in females versus males (Figure 6). As seen
in the Figure, females had similar or slightly higher base-
line pSTAT1 levels, and reduced induction with IL-6 sti-
mulation (seen by reduced 90
th percentile fluorescence
values and reduced stim/unstim ratios). These differences
were consistent across three different cohorts (Projects), as
segregated in the columns of Figure 6A. The results are
shown graphically in Figure 6B. The obvious hypothesis,
which remains to be tested, is that chronically high levels
of IL-6 lead to reduced inducibility of pSTAT1 upon IL-6
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Figure 6 OLAP integration of data from disparate types of assays and multiple projects, with demographic metadata. (A) Serum IL-6 as
measured by MSD assay is compared to CD4+ pSTAT1 expression as measured by phosphoepitope flow cytometry (baseline and IL-6-stimulated
pSTAT1 MFI, as well as fold-change (stim/unstim) are all shown). Data for three healthy cohorts (Projects) are displayed in columns, broken out
by gender. (B) Graphing the mean serum IL-6 levels as a function of mean CD4+ pSTAT1 IL-6 stim/unstim ratios for males and females in each
study shows higher serum IL-6 means in females, and correspondingly lower pSTAT1 induction in response to IL-6 stimulation in CD4+ T cells. A
possible hypothesis is that chronically high IL-6 levels in females result in poorer pSTAT1 induction in response to IL-6.
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aggregate data from dissimilar assays in the same view,
across the same cohorts, to easily find relationships that
may have biological relevance.
Of course, potential findings from SDM, such as those
above, need to be followed up with additional tests, such
as determination of statistical significance and correlation.
Further studies, to test the hypotheses generated, may also
be warranted. But SDM can be used as a starting point to
find relationships and generate hypotheses that can even-
tually lead to new mechanistic understandings, and devel-
opment of new diagnostics and therapeutics.
Discussion
One of our goals was to allow investigators without
advanced computational skills to interact more fully with
their data, allowing them to explore large and heteroge-
neous data sets easily. We have been able to achieve this
using an OLAP interface that enables investigators to for-
mulate and test hypotheses in real time. As an example,
one can display serum cytokine results in rows, and gender
in columns; it then becomes a simple task to scan the rows
to look for gender-specific cytokine differences. Upon
finding such, a quick drill-through can determine whether
these differences are the result of rare outliers or are per-
vasive. The built-in graphing functions of JasperServer can
also aid in this sort of simple data mining.
Another goal of the project was to integrate data across
projects. Thus, if the same standardized assays were
applied in multiple studies, one can compare analytes in
disease X to those in disease Y. Or, one can draw a set of
age- and gender-matched controls from one study and
compare them to patients with disease from another study.
The SDM interface was not designed to be an advanced
statistical tool, nor a suite with sophisticated visualization
functions. Instead, our goal here was to provide simple
ways to filter and display data sets of interest, which can
then be extracted for further analysis in tools such as R (a
language and environment for statistical computing and
graphics), Spotfire (data visualization software), or custom
applications. Because the data is first integrated into the
dimensional model in a relational database, data is accessi-
ble both through the OLAP interface and through these
other tools. In addition, because of its use of the popular
and pervasive programming language Java and open-
source software products, the implementation facilitates
future integration with other technologies of interest in
this space. One example is Weka, a collection of machine
learning algorithms for data mining tasks, such as decision
trees [13]. Notably, these general-purpose data analysis
tools are assay agnostic. In many cases, the same tools can
be used to analyze data from multiple assays, and from the
integrated data set. This reduces the need for investigators
to familiarize themselves with platform-specific data analy-
sis tools and algorithms.
One caveat of data aggregation is the need to account
for assay differences and batch effects. For example, inte-
gration of data across sites requires standardization, or at
least harmonization, of the assay protocols and readouts.
Efforts to this effect are underway, for example, for flow
cytometry immunophenotyping [14]. Even within a single
lab, batch effects can be pronounced, particularly for func-
tional assays such as phosphoepitope flow cytometry.
Batch normalization routines may be required to accu-
rately compare data from different experiments. We plan
to integrate such routines into SDM in future work.
The use of both open-source components and cloud
servers contributed to rapid deployment and low ongoing
cost structure. Cloud servers can be procured in minutes.
Open source software components (MySQL, JBoss,
JasperServer) are readily available for installation and
configuration. In addition, once software is installed and
configured on one server, additional servers can be
cloned from the disk image of the first server.
A limitation of this system is the fact that it currently
deals only with data post-processing (e.g., gated flow cyto-
metry output, or analyzed Luminex reports). In an ideal
system, raw data files would be linked with processed data,
such that re-processing could update the data in real time.
Such systems exist for single-platform data (e.g., Cytobank
for flow cytometry [15], and Stanford Microarray Database
(SMD) for gene expression data [16]). However, these
databases, while extremely useful, are focused on single-
experiment analysis, rather than aggregation across many
experiments; and they are compatible with only a single
data platform. SDM could be expanded to provide links to
raw data files, possibly through interfaces to CytoBank and
SMD. The Data Miner is unlikely to itself become a tool
for initial data analysis and feature extraction (e.g. gating
of flow cytometry files or microarray image quantification),
given the disparate data types and existing dedicated soft-
ware for analysis of such raw data.
Similarly, SDM does not provide complete experimental
protocols or details of sample processing, such as might be
found in an electronic notebook. Instead, the batch run
date provides a pointer to wherever such information is
kept. Future development might involve linking SDM to
an electronic notebook system, so that retrieval of this
type of information becomes seamless.
Conclusion
In conclusion, we have demonstrated that standard tech-
niques of data warehousing can be applied to integrate
and analyze heterogeneous immunological data from
human participants. Within the first 4 months of opera-
tion, 2.8 million rows of data representing results from
Siebert et al. Journal of Translational Medicine 2012, 10:62
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Page 9 of 10237 sets of batch results across 46 projects were loaded
into SDM. Furthermore, by leveraging open-source busi-
ness intelligence software for investigator-driven data
exploration and by deploying on cloud servers, we were
able to meet our design goal of delivering a functional
system within a reasonable time frame and cost (< 1 year
and < $100,000; new instances based on the same code
would obviously be much faster and cheaper). We also
delivered a system that allows users to enter, map, and
explore their data without relying on programmer inter-
vention. We felt that this was critical to our philosophy
of allowing biologists to interact with their data as much
as possible. Finally, we achieved our design goal of
accommodating multiple projects and investigators,
which allows for data integration across assay platforms
and studies. Thus, our system facilitates collaboration
and re-use of data via comparison with new data sets
over time. This is critical to the optimal use of large data
sets consisting of disparate data types, which are becom-
ing common in systems-level studies.
Additional material
Additional file 1: Video S1 Screen capture video of Sherpa interface
for uploading batch results.
Additional file 2: Video S2, Screen capture video of Sherpa interface
for uploading experiment metadata.
Additional file 3: Video S3, Screen capture video of Sherpa interface
for mapping batch results to samples.
Additional file 4: Table S1.
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